Limits...
Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.

Castel LD, Wallston KA, Saville BR, Alvarez JR, Shields BD, Feurer ID, Cella D - Patient Relat Outcome Meas (2015)

Bottom Line: Women with joint comorbidities tended to have higher PRAI scores than those without (estimated difference in mean scores: -0.3, 95% confidence interval [CI] -0.5, -0.2; P<0.001).The PRAI was highly correlated with the Functional Assessment of Cancer Therapy-Endocrine Subscale item "I have pain in my joints" (reference instrument; Spearman r range: 0.76-0.82).We conclude that the psychometric properties of the PRAI are satisfactory for measuring arthralgia severity.

View Article: PubMed Central - PubMed

Affiliation: Meharry-Vanderbilt Alliance, Nashville, TN, USA.

ABSTRACT

Background: There is a need for a survey instrument to measure arthralgia (joint pain) that has been psychometrically validated in the context of existing reference instruments. We developed the 16-item Patient-Reported Arthralgia Inventory (PRAI) to measure arthralgia severity in 16 joints, in the context of a longitudinal cohort study to assess aromatase inhibitor-associated arthralgia in breast cancer survivors and arthralgia in postmenopausal women without breast cancer. We sought to evaluate the reliability and validity of the PRAI instrument in these populations, as well as to examine the relationship of patient-reported morning stiffness and arthralgia.

Methods: We administered the PRAI on paper in 294 women (94 initiating aromatase inhibitor therapy and 200 postmenopausal women without breast cancer) at weeks 0, 2, 4, 6, 8, 12, 16, and 52, as well as once in 36 women who had taken but were no longer taking aromatase inhibitor therapy.

Results: Cronbach's alpha was 0.9 for internal consistency of the PRAI. Intraclass correlation coefficients of test-retest reliability were in the range of 0.87-0.96 over repeated PRAI administrations; arthralgia severity was higher in the non-cancer group at baseline than at subsequent assessments. Women with joint comorbidities tended to have higher PRAI scores than those without (estimated difference in mean scores: -0.3, 95% confidence interval [CI] -0.5, -0.2; P<0.001). The PRAI was highly correlated with the Functional Assessment of Cancer Therapy-Endocrine Subscale item "I have pain in my joints" (reference instrument; Spearman r range: 0.76-0.82). Greater arthralgia severity on the PRAI was also related to decreased physical function (r=-0.47, 95% CI -0.55, -0.37; P<0.001), higher pain interference (r=0.65, 95% CI 0.57-0.72; P<0.001), less active performance status (estimated difference in location (-0.6, 95% CI -0.9, -0.4; P<0.001), and increased morning stiffness duration (r=0.62, 95% CI 0.54-0.69; P<0.0001).

Conclusion: We conclude that the psychometric properties of the PRAI are satisfactory for measuring arthralgia severity.

No MeSH data available.


Related in: MedlinePlus

Baseline mean Patient-Reported Arthralgia Inventory scores by presence of joint comorbidity.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4524452&req=5

f3-prom-6-205: Baseline mean Patient-Reported Arthralgia Inventory scores by presence of joint comorbidity.

Mentions: With regard to validity, Figure 3 shows boxplots of baseline PRAI scores for those participants with and without joint comorbidities. The estimated difference in mean scores between groups was −0.3 (CI −0.5, −0.2; P<0.001). As expected, women with joint comorbidities tended to have higher arthralgia severity scores than those without joint comorbidities. The Wilcoxon rank-sum test of the hypothesis that both groups had the same distribution of scores was highly significant (P<0.001), suggesting known-groups validity with respect to joint comorbidity.


Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.

Castel LD, Wallston KA, Saville BR, Alvarez JR, Shields BD, Feurer ID, Cella D - Patient Relat Outcome Meas (2015)

Baseline mean Patient-Reported Arthralgia Inventory scores by presence of joint comorbidity.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4524452&req=5

f3-prom-6-205: Baseline mean Patient-Reported Arthralgia Inventory scores by presence of joint comorbidity.
Mentions: With regard to validity, Figure 3 shows boxplots of baseline PRAI scores for those participants with and without joint comorbidities. The estimated difference in mean scores between groups was −0.3 (CI −0.5, −0.2; P<0.001). As expected, women with joint comorbidities tended to have higher arthralgia severity scores than those without joint comorbidities. The Wilcoxon rank-sum test of the hypothesis that both groups had the same distribution of scores was highly significant (P<0.001), suggesting known-groups validity with respect to joint comorbidity.

Bottom Line: Women with joint comorbidities tended to have higher PRAI scores than those without (estimated difference in mean scores: -0.3, 95% confidence interval [CI] -0.5, -0.2; P<0.001).The PRAI was highly correlated with the Functional Assessment of Cancer Therapy-Endocrine Subscale item "I have pain in my joints" (reference instrument; Spearman r range: 0.76-0.82).We conclude that the psychometric properties of the PRAI are satisfactory for measuring arthralgia severity.

View Article: PubMed Central - PubMed

Affiliation: Meharry-Vanderbilt Alliance, Nashville, TN, USA.

ABSTRACT

Background: There is a need for a survey instrument to measure arthralgia (joint pain) that has been psychometrically validated in the context of existing reference instruments. We developed the 16-item Patient-Reported Arthralgia Inventory (PRAI) to measure arthralgia severity in 16 joints, in the context of a longitudinal cohort study to assess aromatase inhibitor-associated arthralgia in breast cancer survivors and arthralgia in postmenopausal women without breast cancer. We sought to evaluate the reliability and validity of the PRAI instrument in these populations, as well as to examine the relationship of patient-reported morning stiffness and arthralgia.

Methods: We administered the PRAI on paper in 294 women (94 initiating aromatase inhibitor therapy and 200 postmenopausal women without breast cancer) at weeks 0, 2, 4, 6, 8, 12, 16, and 52, as well as once in 36 women who had taken but were no longer taking aromatase inhibitor therapy.

Results: Cronbach's alpha was 0.9 for internal consistency of the PRAI. Intraclass correlation coefficients of test-retest reliability were in the range of 0.87-0.96 over repeated PRAI administrations; arthralgia severity was higher in the non-cancer group at baseline than at subsequent assessments. Women with joint comorbidities tended to have higher PRAI scores than those without (estimated difference in mean scores: -0.3, 95% confidence interval [CI] -0.5, -0.2; P<0.001). The PRAI was highly correlated with the Functional Assessment of Cancer Therapy-Endocrine Subscale item "I have pain in my joints" (reference instrument; Spearman r range: 0.76-0.82). Greater arthralgia severity on the PRAI was also related to decreased physical function (r=-0.47, 95% CI -0.55, -0.37; P<0.001), higher pain interference (r=0.65, 95% CI 0.57-0.72; P<0.001), less active performance status (estimated difference in location (-0.6, 95% CI -0.9, -0.4; P<0.001), and increased morning stiffness duration (r=0.62, 95% CI 0.54-0.69; P<0.0001).

Conclusion: We conclude that the psychometric properties of the PRAI are satisfactory for measuring arthralgia severity.

No MeSH data available.


Related in: MedlinePlus